RxDoctor Payments Data

Mitchell Keel, MD

Internal Medicine · Newport, ARNPI 1114480209

Payments from drug & device makers

$1,901in general payments, 2019–2025

Across 112 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$737
  • Otsuka America Pharmaceutical, Inc.$258
  • Novo Nordisk$172
  • E.r. Squibb & Sons, L.L.C.$134
  • GSK$114
  • Lilly USA, LLC$63
  • plus $424 from 14 others

What the payments were for

  • Food & beverage$1,79294%
  • Education$1096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,901 in reported general payments places this provider in the 80th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$138,183
Medicare patients
401
Services billed
3,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide196$221,401
EliquisApixaban359$172,937
JardianceEmpagliflozin155$108,096
RybelsusSemaglutide81$94,827
OzempicSemaglutide78$83,454
FarxigaDapagliflozin Propanediol105$74,025
XifaxanRifaximin24$70,648
RexultiBrexpiprazole80$58,723
Invega SustennaPaliperidone Palmitate15$49,997
JanuviaSitagliptin Phosphate75$48,743
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$44,079
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$37,097
XareltoRivaroxaban65$28,378
LinzessLinaclotide25$25,171
Soliqua 100-33Insulin Glargine/Lixisenatide29$25,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Olanzapine$63$226,624349 claims
Novo NordiskRybelsus, Ozempic, Levemir$172$186,671182 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$31$138,020200 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$28$120,831188 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$114$71,902121 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$18$70,64824 claims
Otsuka America Pharmaceutical, Inc.Rexulti$258$58,72380 claims
AbbVieLinzess$737$25,17125 claims
NovartisEntresto$37$10,37016 claims
Astellas Pharma US IncMyrbetriq$34$6,90230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Newport

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →